Clinical Trial

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

Study acronym: BENCHMARK-SLE
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to characterize the efficacy and safety of current standard of care treatment options in participants with active systemic lupus erythematosus (SLE; including lupus nephritis) with inadequate response to glucocorticoids and at least two immunosuppressants
Protocol Amendment History 3 changes
notable Trial sites expanded: 58 -> 62 locations 2026-06-03
notable Trial sites expanded: 54 -> 58 locations 2026-05-19
notable Trial sites expanded: 49 -> 52 locations 2026-04-09
Trial Details
NCT Number NCT07175285
Lead Sponsor Bristol-Myers Squibb
Conditions Systemic Lupus Erythematosus (SLE)
Enrollment 223 participants
Start Date 2025-10-08
Primary Completion 2028-03-24 (estimated)
Study Completion 2032-10-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-21